Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Brilinta/Bydureon’s Measurable Outcomes Are Smooth Fit For Contracts

May 31 2017

• By Cathy Kelly

Related Content

AstraZeneca's 13 Outcomes-Based Contracts Show “Proactive" Engagement On New Models

May 31 2017

Disappointing Bydureon EXSCEL Outcomes Data May Raise Stakes For Victoza

May 23 2017

AstraZeneca Says $3.5bn Brilinta Sales Forecast By 2023 Now Unattainable

Oct 04 2016

Brilinta No Better Than Aspirin In Stroke Trial

Mar 24 2016

Lilly's Performance Contract For Trulicity Hinges On Head-To-Head Superiority

Jun 29 2016

Outcomes-Based Contracts Aren’t So Easy, Harvard Pilgrim Cautions

Jun 02 2016

Related Companies

AstraZeneca PLC

Novo Nordisk A/S

Express Scripts Holding Company

Cigna Corp.

Eli Lilly and Company

Additional Topics

United States Policy Pricing Strategies Market Access

More from Pricing Debate

More from Market Access

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window